Early lipid increases on HAART represent return to normal level for age group

This article is more than 21 years old.

A

review of lipid increases after commencing HAART in 50 HIV seroconverters from

the Multicenter AIDS Cohort Study (MACS) shows that many people are

Glossary

cholesterol

A waxy substance, mostly made by the body and used to produce steroid hormones. High levels can be associated with atherosclerosis. There are two main types of cholesterol: low-density lipoprotein (LDL) or ‘bad’ cholesterol (which may put people at risk for heart disease and other serious conditions), and high-density lipoprotein (HDL) or ‘good’ cholesterol (which helps get rid of LDL).

lipid

Fat or fat-like substances found in the blood and body tissues. Lipids serve as building blocks for cells and as a source of energy for the body. Cholesterol and triglycerides are types of lipids.

seroconversion

The transition period from infection with HIV to the detectable presence of HIV antibodies in the blood. When seroconversion occurs (usually within a few weeks of infection), the result of an HIV antibody test changes from HIV negative to HIV positive. Seroconversion may be accompanied with flu-like symptoms.

 

serum

Clear, non-cellular portion of the blood, containing antibodies and other proteins and chemicals.

 

p-value

The result of a statistical test which tells us whether the results of a study are likely to be due to chance and would not be confirmed if the study was repeated. All p-values are between 0 and 1; the most reliable studies have p-values very close to 0. A p-value of 0.001 means that there is a 1 in 1000 probability that the results are due to chance and do not reflect a real difference. A p-value of 0.05 means there is a 1 in 20 probability that the results are due to chance. When a p-value is 0.05 or below, the result is considered to be ‘statistically significant’. Confidence intervals give similar information to p-values but are easier to interpret. 

experiencing cholesterol elevations that put them back to levels registered

prior to seroconversion. On average, the treated individuals attained lipid

levels that equalled those seen in a large US study of HIV-negative

individuals, suggesting that lipid elevations on HAART represent normalisations

of lipid metabolism, and should only cause concern when they breach the

thresholds laid down in the US NCEP guidelines for managing cardiovascular

risk.

The

findings were presented last week at the Tenth Conference on Retroviruses and

Opportunistic Infections in Boston by researchers from the University of

Pittsburgh, Johns Hopkins University and other participants in the Multicenter

AIDS Cohort Study (MACS).

They

represent the latest effort to determine which lipid increases on HAART pose a

serious risk of cardiovascular disease, and follow on from the observation of

cholesterol declines prior to the introduction of HAART in untreated people

with HIV.

The

researchers identified 50 men who had baseline cholesterol measurements

recorded on entry to the cohort, and who subsequently became infected with HIV

during the 1980s. Lipid measurements were subsequently recorded at four time

points: prior to commencing HAART, and on three occasions during an average

follow-up of three years on HAART. These measurements were compared with

average levels found in the NHANES III cohort study, which collected

information on lipid levels in the non-HIV infected male population aged 20 and

above.

The

interval between the baseline measurement and the last measurement on HAART

averaged 11.6 years, with an average of three years spent on HAART.

Lipid changes from pre-seroconversion baselines

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman";

color:white'>Cholesterol (mg/dl)

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman";

color:white'>baseline

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman";

color:white'>Post-seroconversion

style='font-family:Arial;mso-bidi-font-family:"Times New Roman";color:maroon'>

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman";

color:white'>Change from baseline after 3 years HAART

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman";

color:maroon'>

Total cholesterol

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman"'>203

(+/- 48)

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman"'>-30

 

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman"'>

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman"'>+50

 

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman"'>

HDL cholesterol

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman"'>52

(+/- 14)

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman"'>-12

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman"'>-9

LDL cholesterol

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman"'>121

(+/- 37)

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman"'>-22

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman"'>+21

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman"'> 

Proportions with elevations above NCEP recommended levels,

and p value compared to baseline

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman"'> 

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman";

color:white'>Cholesterol threshold (mg/dl)

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman";

color:white'>baseline

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman";

color:white'>Post-seroconversion

style='font-family:Arial;mso-bidi-font-family:"Times New Roman";color:maroon'>

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman";

color:white'>After 3 years HAART

style='font-family:Arial;mso-bidi-font-family:"Times New Roman";color:maroon'>

Total cholesterol > 240

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman"'>20%

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman"'>4%

(p

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman"'>29%

(ns)

HDL cholesterol

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman"'>16%

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman"'>68%

(p

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman"'>44%

LDL cholesterol > 160

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman"'>18%

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman"'>2%

(p

lang=EN-US style='font-family:Arial;mso-bidi-font-family:"Times New Roman"'>19%

(ns)

The

investigators say that the increases seen after commencing HAART resulted in a

return of cholesterol to the level that would be expected in individuals of

that age (the mean age of seroconverters was 34).

The

researchers concluded that HIV infection results in reductions in total

cholesterol, HDL and LDL cholesterol, but that HDL cholesterol still remains

below pre-infection levels after starting HAART. They recommend longer term

follow-up to determine whether further changes in cholesterol match those seen

with aging, or whether they exceed the elevations seen in the general

population.

Reference

style='font-size:12.0pt;font-family:"Times New Roman"'>Riddler S et al.

lang=EN-US>

style='font-size:12.0pt;font-family:Arial;font-weight:normal'>Serum lipids and

antiretroviral therapy among HIV-infected men. Tenth Conference on Retroviruses

and Opportunistic Infections, Boston, February 10-14, 2003, abstract 750.

lang=EN-US>